Skip to main content

Mankind Pharma seeks CDSCO’s nod to conduct Phase 1 Clinical Trials of patented first in class Novel Anti-Diabetic Molecule

 Mankind Pharma, the 4th largest pharmaceutical comp

any in India (As per IQVIA) today submitted its first Investigational New Drug (IND) application for approval to the Indian Drug Regulatory Authority, Central Drugs Standard Control Organisation(CDSCO) for MKP10241, a patented first in Class Novel Anti Diabetic Molecule.


The company has worked relentlessly in developing this new class of anti-diabetic molecules- designed and developed at the Mankind Research Centre. MKP10241 is a potent and orally administered small molecule, GPR119 agonist. GPR 119 is highly expressed in pancreatic beta cells and intestinal enteroendocrine cells.


With subsequent approval by CDSCO and launch of this first in class drug, the company strongly anticipates that it will be of immense benefit to the diabetic patients, and will prove to be extremely effective in lowering blood sugar levels.


What makes MKP10241unique is its mechanism of action. GPR119 elevates intracellular secondary messengers such as cAMP inside the cells and promotes postprandial insulin and incretin secretion (GLP-1) in a glucose-dependent manner. This dual mechanism by GPR119 in mediating glucose-dependent insulin secretion is distinct from the currently available therapeutic options for Type 2 diabetes and thus becomes a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.


The small molecules with GPR119 agonist property would help the Indian pharma industry to provide a new therapeutic option in the antidiabetic armamentarium for the cliniciansin the management of type 2 diabetes.


The new drug was tested in multiple preclinical models of Type 2 diabetes to understand the mechanism of action and efficacy, and has shown effective results in reducing blood sugar levels and glycated hemoglobin. MKP10241 elevates plasma insulin as well as plasma GLP-1 levels ultimately leading to reduced plasma glucose in preclinical models validating the dual mechanism of action associated with GPR119.


MKP10241 has already been granted patents worldwide till 2037.


Speaking on this historicoccasion, Shri RC Juneja, Executive Chairman, Mankind Pharma said, "Our team of scientists have worked tirelessly& with immense passionto develop this novel drug to benefit the people, and it will be affordable for patients. Mankind Pharma is committed to expanding its portfolio of products in the Indian market in all major therapeutic areas for the benefit of patients, prescribers and the healthcare system.”


The company believes if we can provide the right drug in right dosesto the right patient by the right route at the right time; it will eventually strengthen &improve the health care system effectively. The company has a strong presence in pharmaceutical, veterinary, OTC & FMCG segments. 


Warmest Congratulations to all Mankindians& especially our esteemed scientists at Mankind Research Centre.

Popular posts from this blog

छतरपुर जिला चिकित्सालय को मिलेअत्याधुनिक जांच उपकरण एस्सेल माइनिंग द्वारा सी-आर्म, रक्त जांच एवं अन्य उपकरण दान

 छतरपुर की स्वास्थ्य अधोसंरचना को मजबूत बनाने के ध्येय को आगे बढ़ाते हुए एस्सेल माइनिंग द्वारा शुक्रवार को छतरपुर जिला चिकित्सालय में अत्याधुनिक सी-आर्म इमेजिंग डिवाइस, हाई फ़्लो नैज़ल कैनुला समेत त्वरित रक्त जांच उपकरण एवं मोरचुरी फ्रीजर भेंट किया गया।  जिला कलेक्टर श्री संदीप जी आर ने फीता काटकर नई सुविधाओं का शुभारंभ किया। इस अवसर पर मुख्य चिकित्सा एवं स्वास्थ्य अधिकारी डॉ विजय पथोरिया एवं अस्पताल के अन्य अधिकारी-कर्मचारी उपस्थित रहे। नए उपकरणों के साथ छतरपुर जिला चिकित्सालय के सुविधाओं में वृद्धि होने के साथ ही हजारों नागरिकों को नई जाँचों का लाभ मिल सकेगा और त्वरित जांच प्राप्त हो सकेगी।कलेक्टर श्री श्री संदीप जी आर द्वारा इस अवसर पर अस्पताल परिसर में पौधा रोपण भी किया गया।  एस्सेल माइनिंग द्वारा लगातार छतरपुर जिले की स्वास्थ्य सेवाओं को उन्नत बनाने में सतत योगदान दिया जा रहा है। पूर्व में गुरुवार को कंपनी द्वारा बक्सवाहा के सामुदायिक स्वास्थ्य केंद्र को बड़ा मलहरा विधायक श्री प्रद्युम्न सिंह लोधी की उपस्थिति में एडवांस्ड लाइफ सपोर्ट एम्बुलेंस भेंट की गई। वेंटीलेटर जैसी सुविधाओं के सा

*Reusable pads essential to make menstrual hygiene sustainable for all women and girls*

 If every woman and girl of menstruating age in India used disposable pads, 38,500,000,000 used pads would be discarded every month – an environmental disaster since each of these would take 500-800 years to degrade naturally XXX / May 26, 2021: Considering the immense non-biodegradable waste generated by disposable sanitary pads every month, sustainable menstrual hygiene in India can be achieved only with reusable pads made of organic material, said Anju Bist, Co-Director, Amrita SeRVe (Self Reliant Village) Program of Mata Amritanandamayi Math. Known as the “Pad Woman” of India for her zeal in promoting the use and reuse of sanitary pads made of cloth and banana fibre, she is the co-creator of Saukhyam Reusable Pads which have been awarded as the "Most Innovative Product" by the National Institute of Rural Development, Hyderabad. The pads were also lauded at the UN Climate Change Conference held in Poland in 2018. Said Anju Bist: “There are 355 million menstruating women an


 12-year-old boy with rare liver disease undergoes successful multi-organ transplant making him the 2nd case in the world and 1st in the country Chennai, 7th December, 2021: Gleneagles Global Health City (GGHC), a leading multi-organ transplant centre in Asia, successfully performed India’s first live donor liver and kidney transplant on a 12-year-old who was suffering from a rare genetic disorder – Primary Hyperoxaluria type 2. Master Anish*, a 12-year-old, was referred from Bangalore with renal failure and had been on dialysis three times a week. Doctors in Bangalore had diagnosed him with a rare genetic disorder called Primary Hyperoxaluria (PH) type- II, which is a liver condition that results in accumulation of oxalate in the kidneys, heart and bones and other organ systems of the body. As the disease is primarily based in the liver, these patients need combined liver and kidney transplantation for cure which is a major undertaking, especially in a child.  Across the world, there